13/09/2017 18:05:41

RxS moves to new location to accommodate rapid growth

MANALAPAN, NJ, Sept. 13, 2017 (GLOBE NEWSWIRE) -- RxS LLC (“RxS”), a privately held company providing multi-channel sample management solutions to pharmaceutical and biotech companies, announced today its move to a new location to accommodate the company’s continued growth and success. Remaining in Manalapan, NJ, RxS is now operating at:

195 Route 9 S., Suite 208

Manalapan, NJ 07726

Pharmaceutical and biotech companies are often burdened by the regulations surrounding sample management, and that’s where RxS comes in. RxS offers customizable solutions for multi-channel sample management to companies of all sizes, ensuring compliance, state-of-the-art reporting, and outstanding customer service. “We are a service organization enabled by technology,” says Mark Jara, Principal, Managing Director. “Because RxS has proven to be a valuable business partner for so many companies, RxS has moved to a new location to accommodate our growth and success.”

RxS has maintained organizational growth year after year, including sales, clients, employees, and services.  Over the past two years they had a surge in new clients and business expansion. The new office space will support RxS’s promising trajectory as well as creating a high tech collaborative environment to optimize customer service and enhance technical development.

The move, however, is just one of several new developments for RxS. Concurrent to this action, the company is continuing the growth of its European footprint. In addition, RxS has entered the planning phase for a proposed satellite location in southeastern Florida slated to open by mid-2018.

RxS has become a leading provider of multi-channel sample management solutions. RxS’s growing presence and continued success is credited to its leadership team that collectively has more than 75 years of pharmaceutical expertise, along with the employees’ immense knowledge and understanding of the pharma and biotech industries. Beyond that, RxS has been built on technology and is committed to providing superior customer service.

By having technology at its core, RxS can provide offerings that ensure Prescription Drug Marketing Act compliance and also supply valuable reporting and analytics data. Customers can access up-to-date reporting and analytics data 24 hours a day, seven days a week, a feature that makes proactive monitoring possible. This results in customers having the tools to advance marketing reach and optimizing sample effectiveness.

Customer service is paramount to the team at RxS. In the client-supplier relationship, the company views itself as a business partner rather than simply a vendor as account representatives learn each client’s needs and provide client centric solutions designed to drive success. RxS has found this to be a most effective approach, as the solutions they provide clients are transparent and value-centric in terms of pricing.

RxS’s success is a direct reflection of the value it has provided and continues to provide its customers. For example, by applying industry experiences and a consultative approach, RxS was able to provide a small-sized client with guidance on best practices, lead-in project management and technical integrations during their first prescription representative product sampling launch. The result was an overwhelming success that relieved the client of startup complexities while achieving compliance through a solid forward thinking framework, on time and on budget.

The value RxS provides customers extends also to more established pharmaceutical and biotech companies. For instance, a client needed to transition from having multiple vendors to a consolidated solution, so RxS provided such a solution and also strategic value during the transition. RxS achieved this by working with numerous internal and external stakeholders to identify scope and requirements. The outcome was a solution that met the deadline and budget and also had a positive impact throughout the company, from headquarters to customers.

RxS works with companies of all sizes and provides truly client centric solutions that meet each client’s needs. To learn more about RxS offerings please visit rxsinfo.com. To schedule a visit to their new headquarters, please email sales@rxsinfo.com.

About RxS LLC

RxS LLC, a privately held company in Manalapan, New Jersey, is the leading provider of multi-channel sample management solutions for pharmaceutical and biotech companies. Supported by more than   75 years of combined pharmaceutical leadership experience, RxS has been partnering with pharmaceutical and biotech companies since its founding in 2011 to provide regulatory compliance in order to lessen the administrative burden of the Prescription Drug Marketing Act. RxS offerings go beyond regulatory compliance, providing solutions to increase marketing and sample effectiveness. Driven by technology, RxS offers a suite of proprietary services and software solutions to ensure regulatory compliance and maximize analytics data.

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3fa66210-a0be-4307-b66f-3fc3e92e4361

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2c04c05e-388c-4cc6-a173-cef94eb39845

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/47e38a37-f9b1-41d3-883a-9ba03c746912

Drew Deeter

RxS

2153483890

drew@deeterusa.com

RxS moved to new office at 195 Route 9 S., Suite 208, Manalapan, NJ 07726

Interior photo of new RxS home office building.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jan
OMXC25
@ Poppelkongen: Jeg tror ski da, at du har misforstået brugen af filteret?! Når du nævner, at du er..
37
17 Jan
 
Hej alle,   Nu hvor jeg tager et sabat-år som investor i 2018, tænkte jeg, at jeg ville lave en upda..
26
19 Jan
 
Jeg har på en fornemmelsen at i ikke bryder jer om mig? Ik sandt? Så har overvejet at stoppe på EI. ..
24
15 Jan
BEO-SDB
Godmorgen,   Som langt størstedelen af jer der har investeret i BEO ved, afventer vi svar fra Bergst..
18
20 Jan
 
Jeg stiller mig tvivlende,,,,,: At som dansk at betale til Prins Henrik & Co der skider DK en hatful..
17
19 Jan
 
Måske du bare skulle revurdere din adfærd og generelle ageren?
16
15 Jan
VWS
Vi har snakker Vestas Service en gang i dag, men jeg tror, at selv Vestas Group er overrasket over, ..
16
18 Jan
VWS
Utroligt, at det nu i flere år har været muligt og lovligt at handle under dæknavnet "Anonymous Brok..
15
20 Jan
TEVA
Mit råd er at lade være med at lytte til andre. Beslut dig, hvad du synes Teva er værd. Hvis den nuv..
14
19 Jan
NOVO-B
Novo/Goldman: Kursmålet hæves med godt 30 pct. 19/1/2018 06.34· Ritzau Finans Den danske medicinalgi..
14

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

19/01/2018 15:28:15
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Invesco Ltd. : Form 8.3 - Informa Plc

Related news
19/01/2018 13:58:51
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Invesco Ltd. (b) Owner or control..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

19/01/2018 10:18:53
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Vera Bradley Annual Outlet Sale Tickets Available January 22, 2018
2
Gala Pharmaceuticals Sees 2018 as Breakthrough Year for Company
3
Aluminum Association Responds to Submission of Section 232 Report to the President

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 January 2018 23:57:07
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180112.1 - EUROWEB7 - 2018-01-22 00:57:07 - 2018-01-21 23:57:07 - 1000 - Website: OKAY